BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,307,674 | -15.8% | 63,283 | +1.0% | 0.07% | -12.0% |
| Q2 2023 | $5,114,691 | +8.3% | 62,657 | -1.6% | 0.08% | +2.7% |
| Q1 2023 | $4,724,048 | -6.5% | 63,675 | +4.5% | 0.07% | -9.9% |
| Q4 2022 | $5,051,950 | +12.3% | 60,955 | +284.9% | 0.08% | +2.5% |
| Q3 2022 | $4,498,000 | -19.7% | 15,836 | -2.0% | 0.08% | -16.0% |
| Q2 2022 | $5,602,000 | -22.6% | 16,162 | -3.3% | 0.09% | -8.7% |
| Q1 2022 | $7,236,000 | -19.8% | 16,710 | -4.2% | 0.10% | -14.2% |
| Q4 2021 | $9,020,000 | +6.9% | 17,437 | +0.2% | 0.12% | 0.0% |
| Q3 2021 | $8,436,000 | +2.6% | 17,410 | -4.7% | 0.12% | +2.6% |
| Q2 2021 | $8,224,000 | +15.6% | 18,262 | -2.0% | 0.12% | +6.4% |
| Q1 2021 | $7,117,000 | +6.3% | 18,635 | -11.6% | 0.11% | -1.8% |
| Q4 2020 | $6,693,000 | +28.3% | 21,074 | +0.1% | 0.11% | +10.9% |
| Q3 2020 | $5,217,000 | -5.3% | 21,053 | +0.9% | 0.10% | -11.4% |
| Q2 2020 | $5,507,000 | +40.9% | 20,856 | +1.2% | 0.11% | +18.8% |
| Q1 2020 | $3,908,000 | -5.6% | 20,606 | +9.2% | 0.10% | +9.1% |
| Q4 2019 | $4,142,000 | +11.9% | 18,870 | -0.3% | 0.09% | +7.3% |
| Q3 2019 | $3,703,000 | -7.7% | 18,923 | -1.7% | 0.08% | -7.9% |
| Q2 2019 | $4,012,000 | +6.4% | 19,241 | +1.4% | 0.09% | +4.7% |
| Q1 2019 | $3,769,000 | +42.5% | 18,981 | +3.9% | 0.08% | +28.8% |
| Q4 2018 | $2,644,000 | -26.7% | 18,274 | +3.3% | 0.07% | -17.5% |
| Q3 2018 | $3,609,000 | +56.2% | 17,682 | +13.2% | 0.08% | +40.4% |
| Q2 2018 | $2,310,000 | +10.5% | 15,621 | +12.8% | 0.06% | +9.6% |
| Q1 2018 | $2,091,000 | +42.0% | 13,849 | +13.7% | 0.05% | +33.3% |
| Q4 2017 | $1,473,000 | 0.0% | 12,180 | 0.0% | 0.04% | +2.6% |
| Q3 2017 | $1,473,000 | +6.9% | 12,180 | +3.9% | 0.04% | 0.0% |
| Q2 2017 | $1,378,000 | +9.6% | 11,728 | -5.2% | 0.04% | +5.6% |
| Q1 2017 | $1,257,000 | – | 12,371 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |